معرفی
Professor Michael Berk is a NHMRC Level 3 Research Fellow and Alfred Deakin Professor of Psychiatry at Deakin University and Barwon Health. He serves as Director of the Institute for Mental and Physical Health and Clinical Translation (IMPACT) and holds Honorary Professorial Research Fellow positions at the Florey Institute for Neuroscience and Mental Health, Orygen Youth Health, and Monash University's School of Public Health and Preventive Medicine.
Education:
- Bachelor of Medicine & Bachelor of Surgery (University of Witwatersrand)
Research Interests focus on novel therapy development for psychiatric disorders, particularly mood disorders, schizophrenia, and chronic fatigue syndrome. His work spans biomarker research, drug safety, internet-based therapies, and early intervention strategies. Recent publications highlight advances in machine learning applications for depression management, genomic risk prediction, and pharmacoepigenomic studies of ketamine.
Scientific Awards:
- NHMRC Level 3 Research Fellow
- Thompson Reuters ISI Highly Cited Researcher (2015-2023)
- Alfred Deakin Chair of Psychiatry
As a supervisor, he guides doctoral research in areas including bipolar disorder treatment, biomarker analysis, machine learning in ECT, and novel neurostimulation techniques. His grants cover projects like:
- MRFF Survivorship Care Grant (2025-2028)
- NHMRC Synergy Grants for schizophrenia research (2025-2029)
- US Department of Defense PTSD treatment trial (2023-2027)
- MRFF Innovative Therapies for Mental Illness Grant (2022-2027)
He leads the IMPACT Institute and collaborates with institutions including the Florey Institute, Monash University, and Melbourne University. His professional activities include editorial roles at Australian & New Zealand Journal of Psychiatry and The Lancet Psychiatry, along with leadership positions in the International Society for Bipolar Disorders.
